May 9, 2023

Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Boston, MA – May 9, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.

Presentation Details:

Title: Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease using Cerevance’s NETSseq Platform and Analysis

Overview: Using the NETSseq platform, Cerevance has performed deep transcriptional profiling (>12,000genes) of specific neuronal and glial cell types from the cortex of early-Alzheimer's disease (AD), late-AD, and non-neurodegenerative age-matched control donors.With these biological insights, Cerevance has built, and continues to identify, an internal pipeline of novel therapeutic targets for AD and other neurodegenerative disorders.

Venue: Giuliano Stirparo

About Cerevance

Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 136-patient Phase 2 study in patients with Parkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit



Johnna Simoes,


Andrew Mielach,, +1-646-876-5868